{"id":777819,"date":"2025-12-04T13:22:01","date_gmt":"2025-12-04T13:22:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=777819"},"modified":"2025-12-04T13:22:01","modified_gmt":"2025-12-04T13:22:01","slug":"pharmaceutical-contract-manufacturing-market-global-outlook-growth-drivers-and-emerging-opportunities-20252030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pharmaceutical-contract-manufacturing-market-global-outlook-growth-drivers-and-emerging-opportunities-20252030_777819.html","title":{"rendered":"Pharmaceutical Contract Manufacturing Market: Global Outlook, Growth Drivers, and Emerging Opportunities (2025-2030)"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/12\/1764857856.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Pharmaceutical Contract Manufacturing Market: Global Outlook, Growth Drivers, and Emerging Opportunities (2025-2030)\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/12\/1764857856.jpg\" alt=\"Pharmaceutical Contract Manufacturing Market: Global Outlook, Growth Drivers, and Emerging Opportunities (2025-2030)\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Browse 621 market data Tables and 62 Figures spread through 521 Pages and in-depth TOC on &#8220;Pharmaceutical Contract Manufacturing Market by Service (Drug Development, Pharmaceutical (API, FDF &#8211; Parenteral, Tablet, Capsule), Biologics (API, FDF), Packaging &#038; Labelling, Fill-finish), Molecule (Small, Large (ADC, CGT)) &#8211; Global Forecast to 2030<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Global pharmaceutical contract manufacturing market valued at $193.52B in 2024, $209.90B in 2025, and set to hit $311.95B by 2030, growing at 8.2% CAGR<\/div>\n<p style=\"text-align: justify;\">The <strong>global Pharmaceutical Contract Manufacturing Market<\/strong> continues to demonstrate strong momentum as outsourcing becomes a core strategy for pharmaceutical and biopharmaceutical companies worldwide. Valued at <strong>US$193.99 billion in 2024<\/strong>, the market increased to <strong>US$209.90 billion in 2025<\/strong> and is projected to reach <strong>US$311.95 billion by 2030<\/strong>, representing a <strong>robust CAGR of 8.2%<\/strong> during the forecast period. This growth reflects the rising need for specialized manufacturing solutions, regulatory compliance expertise, and scalable capacity&mdash;especially as the pipeline of complex biologics expands.<\/p>\n<p style=\"text-align: justify;\">Several structural trends are fueling this rapid expansion. The surge in <strong>GLP-1 drug demand<\/strong>, increased outsourcing for <strong>Antibody&ndash;Drug Conjugate (ADC) manufacturing<\/strong>, and the patent expiration of blockbuster biologics are opening the door for advanced biosimilar production. At the same time, evolving regulatory expectations&mdash;such as <strong>Annex-1 revisions<\/strong>, <strong>PFAS restrictions<\/strong>, and mounting pricing pressure on drugs in the US and Europe&mdash;pose challenges for CDMOs and pharmaceutical companies. Despite these hurdles, the contract manufacturing sector continues to expand, supported by innovation and increasing reliance on outsourcing partnerships.<\/p>\n<p style=\"text-align: justify;\"><strong>Download PDF Brochure: <a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=201524381&amp;utm_source=abnewswire.com&amp;utm_medium=paidpr&amp;utm_campaign=pharmaceuticalcontractmanufacturingmarket\"  target=\"_blank\">https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=201524381<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Market Overview and Key Insights<\/strong><\/p>\n<p style=\"text-align: justify;\">The pharmaceutical contract manufacturing landscape is undergoing a major transformation. With more pharmaceutical companies shifting towards leaner operating models, outsourcing has become a strategic approach to optimize cost, accelerate time-to-market, and leverage specialized expertise. Contract development and manufacturing organizations (CDMOs) offer a full spectrum of services&mdash;from drug development and formulation to large-scale biologics and fill-finish operations.<\/p>\n<p style=\"text-align: justify;\">The industry&rsquo;s growth is deeply connected to market dynamics such as:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Increased demand for <strong>high-potency and complex drugs<\/strong><\/p>\n<\/li>\n<li>\n<p>Expansion of <strong>biosimilar pipelines<\/strong><\/p>\n<\/li>\n<li>\n<p>Need for <strong>global supply chain resilience<\/strong><\/p>\n<\/li>\n<li>\n<p>Rising investments in <strong>advanced biomanufacturing technologies<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The availability of an extensive infrastructure, skilled talent pool, and regulatory-aligned facilities positions leading CDMOs as indispensable partners for pharma and biotech innovators.<\/p>\n<p style=\"text-align: justify;\"><strong>Market Segmentation by Service<\/strong><\/p>\n<p style=\"text-align: justify;\">The pharmaceutical contract manufacturing market is divided into several key services:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Drug development services<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Pharmaceutical manufacturing services<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Biologic manufacturing services<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Packaging &amp; labelling services<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Fill-finish services<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Other specialized services<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Pharmaceutical Manufacturing Leads the Market<\/strong><\/p>\n<p style=\"text-align: justify;\">In 2024, <strong>pharmaceutical manufacturing services<\/strong> dominated the market. This segment continues to thrive due to:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Increased demand for <strong>innovative and generic drugs<\/strong><\/p>\n<\/li>\n<li>\n<p>Need for <strong>large-scale production<\/strong> to meet global healthcare demands<\/p>\n<\/li>\n<li>\n<p>Rising complexity in formulations, including <strong>HPAPIs<\/strong>, <strong>controlled-release drugs<\/strong>, and <strong>sterile injectables<\/strong><\/p>\n<\/li>\n<li>\n<p>Benefits of outsourcing, such as access to <strong>advanced equipment<\/strong>, experienced personnel, and <strong>regulatory expertise<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Manufacturers are increasingly adopting <strong>flexible production models<\/strong>, allowing pharmaceutical companies to adapt quickly to market fluctuations. This adaptability&mdash;combined with enhanced focus on efficiency and reduced time-to-market&mdash;positions pharmaceutical manufacturing services as a central driver of industry growth.<\/p>\n<p style=\"text-align: justify;\"><strong>Sub-segmentation: API vs. FDF Manufacturing<\/strong><\/p>\n<p style=\"text-align: justify;\">Within the pharmaceutical manufacturing services category, the market is further divided into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>API (Active Pharmaceutical Ingredient) manufacturing<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>FDF (Finished Dosage Form) manufacturing<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>API Manufacturing Dominates in 2024<\/strong><\/p>\n<p style=\"text-align: justify;\">The <strong>API manufacturing segment<\/strong> is set to claim the largest share in 2024. This dominance is fueled by:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Growth in demand for APIs due to the rise of <strong>chronic and lifestyle diseases<\/strong><\/p>\n<\/li>\n<li>\n<p>Expansion of the global <strong>generics market<\/strong><\/p>\n<\/li>\n<li>\n<p>Increasing complexity of molecules, such as <strong>peptides<\/strong>, <strong>oligonucleotides<\/strong>, and <strong>HPAPIs<\/strong><\/p>\n<\/li>\n<li>\n<p>A global shift toward outsourcing to CDMOs to ensure <strong>cost efficiency<\/strong>, <strong>compliance<\/strong>, and <strong>scalability<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">CDMOs offer specialized containment facilities essential for handling highly potent compounds, making them preferred partners for API production across the industry.<\/p>\n<p style=\"text-align: justify;\"><strong>Regional Outlook: Asia Pacific Leads Growth<\/strong><\/p>\n<p style=\"text-align: justify;\">Geographically, the pharmaceutical contract manufacturing market spans:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>North America<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Europe<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Asia Pacific<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Latin America<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Middle East<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Africa<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Asia Pacific Expected to be the Fastest-Growing Region<\/strong><\/p>\n<p style=\"text-align: justify;\">The <strong>Asia Pacific<\/strong> region is projected to witness the fastest growth due to:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Strong cost advantages<\/p>\n<\/li>\n<li>\n<p>Expanding pharmaceutical manufacturing capabilities<\/p>\n<\/li>\n<li>\n<p>Rapidly growing healthcare infrastructure<\/p>\n<\/li>\n<li>\n<p>Supportive government regulations and investments<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Countries like <strong>China, India, South Korea, and Singapore<\/strong> are emerging as global CDMO hubs. Regional players such as <strong>WuXi Biologics, Asymchem, Piramal Pharma Solutions, Divi&rsquo;s Laboratories<\/strong>, and global giants like <strong>Lonza, Thermo Fisher Scientific, and Boehringer Ingelheim<\/strong> continue to expand their presence to tap into APAC&rsquo;s competitive advantage.<\/p>\n<p style=\"text-align: justify;\">Increasing demand for biosimilars, generics, and next-generation therapies&mdash;combined with favorable trade policies and capacity expansions&mdash;positions the Asia Pacific region as the future backbone of global pharmaceutical contract manufacturing.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Market Players<\/strong><\/p>\n<p style=\"text-align: justify;\">The global pharmaceutical contract manufacturing market is highly competitive, with major companies shaping industry direction. Prominent players include:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Thermo Fisher Scientific (US)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Catalent, Inc. (US)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Lonza (Switzerland)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>WuXi Biologics (China)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Merck KGaA (Germany)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Samsung Biologics (South Korea)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Boehringer Ingelheim (Germany)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Siegfried Holding AG (Switzerland)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Evonik Industries (Germany)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>FUJIFILM Holdings (Japan)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Almac Group (UK)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Asymchem (China)<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Charles River Laboratories (US)<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Thermo Fisher Scientific Inc.<\/strong><\/p>\n<p style=\"text-align: justify;\">Thermo Fisher has strengthened its position through:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Its <strong>Accelerator Drug Development<\/strong> platform, integrating CDMO and CRO services.<\/p>\n<\/li>\n<li>\n<p>Expansion of key manufacturing sites in <strong>Missouri, Ohio, Massachusetts, and North Carolina<\/strong>.<\/p>\n<\/li>\n<li>\n<p>Scalable capabilities to support small molecules, biologics, and advanced therapies.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Catalent, Inc. (Novo Holdings)<\/strong><\/p>\n<p style=\"text-align: justify;\">Catalent remains a leading CDMO, offering expertise in:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Oral, injectable, and respiratory drug delivery<\/p>\n<\/li>\n<li>\n<p>Drug substance manufacturing and formulation<\/p>\n<\/li>\n<li>\n<p>End-to-end commercial manufacturing<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The company recently expanded production at its <strong>Madison facility<\/strong>, enhancing capacity for both clinical and commercial biologics manufacturing.<\/p>\n<p style=\"text-align: justify;\"><strong>Conclusion<\/strong><\/p>\n<p style=\"text-align: justify;\">The <strong>pharmaceutical contract manufacturing market<\/strong> is entering a transformative phase marked by scientific innovation, growth in biologics and biosimilars, and increasing reliance on outsourcing partners. Despite pricing pressures and regulatory challenges, the sector is poised for sustained expansion&mdash;driven by advanced capabilities, global capacity expansions, and rising demand for specialized manufacturing services.<\/p>\n<p style=\"text-align: justify;\"><strong>Request Sample Pages : <\/strong><strong><a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=201524381&amp;utm_source=abnewswire.com&amp;utm_medium=paidpr&amp;utm_campaign=pharmaceuticalcontractmanufacturingmarket\"  target=\"_blank\">https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=201524381<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/marketsandmarkets.com_145966.html\" rel=\"nofollow\">MarketsandMarkets\u2122 Research Private Ltd.<\/a><br \/><strong>Contact Person:<\/strong> Mr. Rohan Salgarkar<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=pharmaceutical-contract-manufacturing-market-global-outlook-growth-drivers-and-emerging-opportunities-20252030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 18886006441<br \/><strong>Address:<\/strong>1615 South Congress Ave.  Suite 103, Delray Beach, FL 33445<br \/><strong>City:<\/strong> Florida<br \/><strong>State:<\/strong> Florida<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/hot-melt-adhesives-market-1088.html\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.marketsandmarkets.com\/Market-Reports\/hot-melt-adhesives-market-1088.html<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=pharmaceutical-contract-manufacturing-market-global-outlook-growth-drivers-and-emerging-opportunities-20252030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Browse 621 market data Tables and 62 Figures spread through 521 Pages and in-depth TOC on &#8220;Pharmaceutical Contract Manufacturing Market by Service (Drug Development, Pharmaceutical (API, FDF &#8211; Parenteral, Tablet, Capsule), Biologics (API, FDF), Packaging &#038; Labelling, Fill-finish), Molecule (Small, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/pharmaceutical-contract-manufacturing-market-global-outlook-growth-drivers-and-emerging-opportunities-20252030_777819.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,416],"tags":[],"class_list":["post-777819","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/777819","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=777819"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/777819\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=777819"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=777819"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=777819"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}